A carregar...
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
PURPOSE: Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability. It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo. Therefore, we conduc...
Na minha lista:
| Publicado no: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7493746/ https://ncbi.nlm.nih.gov/pubmed/31325145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03243-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|